IDH1 and glioma: In addition, we found that the four-lncRNA risk signature can also identify high-risk patients in age ≤ 40 and age > 40; grade prognostic prediction power of four-lncRNA risk signature was not decreased in molecular or clinical factor subgroups of IDH mutant glioma.